Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants

Steven K. Obaro, Richard A. Adegbola, Ih Chang, Winston A.S. Banya, Shabbar Jaffar, Keith W.J.P. McAdam, Brian M. Greenwood

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background. Unrelenting high morbidity and mortality have mandated that immunogenic vaccines be used to combat pneumococcal disease in infants. Objectives. To evaluate the safety and immunogenicity of a nonavalent pneumococcal conjugate vaccine and the antigenic interaction when administered simultaneously with diphtheria, tetanus and pertussis vaccines. Methods. Two hundred seven infants were randomized to receive three doses of either nonavalent protein conjugate pneumococcal vaccine (PnCV) or inactivated polio vaccine (IPV) at 2, 3 and 4 months of age with routine Expanded Program of Immunization vaccines as scheduled. Vaccinees were visited on Days 1, 2 and 7 to observe local and systemic adverse reactions. Blood was drawn before the first dose and 1 month after the third dose. Antibody concentrations in sera were measured by standardized enzyme-linked immunosorbent assay. Nasopharyngeal carriage of pneumococci was tested at 5 and 9 months of age. Results. No serious reactions were observed. Local induration and tenderness were observed more commonly at the site of administration of diphtheria, tetanus and pertussis vaccines than at the site of administration of IPV or PnCV. Between 79 and 91% achieved ≥1 μg/ml antibody against specific pneumococcal serotypes. Antibody responses to diphtheria and pertussis antigens were similar in both groups; however, antibody response to tetanus toxoid was significantly lower in infants who received PnCV (geometric mean concentration, 11.1 vs. 17.4; P < 0.001). Nasopharyngeal carriage in PnCV-vaccinated children was reduced but not significantly different from those vaccinated with IPV. Conclusion. Simultaneous administration of PnCV with Expanded Program of Immunization vaccines is safe and immunogenic. Immune response to the composite antigens is likely to confer protection.

Original languageEnglish (US)
Pages (from-to)463-469
Number of pages7
JournalPediatric Infectious Disease Journal
Volume19
Issue number5
DOIs
StatePublished - May 2000

Fingerprint

Diphtheria-Tetanus-Pertussis Vaccine
Pneumococcal Vaccines
Syringes
Safety
Inactivated Vaccines
Poliomyelitis
Immunization Programs
Conjugate Vaccines
Vaccines
Antibody Formation
Antigens
Tetanus Toxoid
Diphtheria
Antibodies
Whooping Cough
Streptococcus pneumoniae
CRM197 (non-toxic variant of diphtheria toxin)
Enzyme-Linked Immunosorbent Assay
Morbidity
Mortality

Keywords

  • Immunogenicity
  • Pneumococcal conjugate vaccine
  • Safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. / Obaro, Steven K.; Adegbola, Richard A.; Chang, Ih; Banya, Winston A.S.; Jaffar, Shabbar; McAdam, Keith W.J.P.; Greenwood, Brian M.

In: Pediatric Infectious Disease Journal, Vol. 19, No. 5, 05.2000, p. 463-469.

Research output: Contribution to journalArticle

@article{a5cb68fe7d6a415f901711ee6fd07f9f,
title = "Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants",
abstract = "Background. Unrelenting high morbidity and mortality have mandated that immunogenic vaccines be used to combat pneumococcal disease in infants. Objectives. To evaluate the safety and immunogenicity of a nonavalent pneumococcal conjugate vaccine and the antigenic interaction when administered simultaneously with diphtheria, tetanus and pertussis vaccines. Methods. Two hundred seven infants were randomized to receive three doses of either nonavalent protein conjugate pneumococcal vaccine (PnCV) or inactivated polio vaccine (IPV) at 2, 3 and 4 months of age with routine Expanded Program of Immunization vaccines as scheduled. Vaccinees were visited on Days 1, 2 and 7 to observe local and systemic adverse reactions. Blood was drawn before the first dose and 1 month after the third dose. Antibody concentrations in sera were measured by standardized enzyme-linked immunosorbent assay. Nasopharyngeal carriage of pneumococci was tested at 5 and 9 months of age. Results. No serious reactions were observed. Local induration and tenderness were observed more commonly at the site of administration of diphtheria, tetanus and pertussis vaccines than at the site of administration of IPV or PnCV. Between 79 and 91{\%} achieved ≥1 μg/ml antibody against specific pneumococcal serotypes. Antibody responses to diphtheria and pertussis antigens were similar in both groups; however, antibody response to tetanus toxoid was significantly lower in infants who received PnCV (geometric mean concentration, 11.1 vs. 17.4; P < 0.001). Nasopharyngeal carriage in PnCV-vaccinated children was reduced but not significantly different from those vaccinated with IPV. Conclusion. Simultaneous administration of PnCV with Expanded Program of Immunization vaccines is safe and immunogenic. Immune response to the composite antigens is likely to confer protection.",
keywords = "Immunogenicity, Pneumococcal conjugate vaccine, Safety",
author = "Obaro, {Steven K.} and Adegbola, {Richard A.} and Ih Chang and Banya, {Winston A.S.} and Shabbar Jaffar and McAdam, {Keith W.J.P.} and Greenwood, {Brian M.}",
year = "2000",
month = "5",
doi = "10.1097/00006454-200005000-00014",
language = "English (US)",
volume = "19",
pages = "463--469",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants

AU - Obaro, Steven K.

AU - Adegbola, Richard A.

AU - Chang, Ih

AU - Banya, Winston A.S.

AU - Jaffar, Shabbar

AU - McAdam, Keith W.J.P.

AU - Greenwood, Brian M.

PY - 2000/5

Y1 - 2000/5

N2 - Background. Unrelenting high morbidity and mortality have mandated that immunogenic vaccines be used to combat pneumococcal disease in infants. Objectives. To evaluate the safety and immunogenicity of a nonavalent pneumococcal conjugate vaccine and the antigenic interaction when administered simultaneously with diphtheria, tetanus and pertussis vaccines. Methods. Two hundred seven infants were randomized to receive three doses of either nonavalent protein conjugate pneumococcal vaccine (PnCV) or inactivated polio vaccine (IPV) at 2, 3 and 4 months of age with routine Expanded Program of Immunization vaccines as scheduled. Vaccinees were visited on Days 1, 2 and 7 to observe local and systemic adverse reactions. Blood was drawn before the first dose and 1 month after the third dose. Antibody concentrations in sera were measured by standardized enzyme-linked immunosorbent assay. Nasopharyngeal carriage of pneumococci was tested at 5 and 9 months of age. Results. No serious reactions were observed. Local induration and tenderness were observed more commonly at the site of administration of diphtheria, tetanus and pertussis vaccines than at the site of administration of IPV or PnCV. Between 79 and 91% achieved ≥1 μg/ml antibody against specific pneumococcal serotypes. Antibody responses to diphtheria and pertussis antigens were similar in both groups; however, antibody response to tetanus toxoid was significantly lower in infants who received PnCV (geometric mean concentration, 11.1 vs. 17.4; P < 0.001). Nasopharyngeal carriage in PnCV-vaccinated children was reduced but not significantly different from those vaccinated with IPV. Conclusion. Simultaneous administration of PnCV with Expanded Program of Immunization vaccines is safe and immunogenic. Immune response to the composite antigens is likely to confer protection.

AB - Background. Unrelenting high morbidity and mortality have mandated that immunogenic vaccines be used to combat pneumococcal disease in infants. Objectives. To evaluate the safety and immunogenicity of a nonavalent pneumococcal conjugate vaccine and the antigenic interaction when administered simultaneously with diphtheria, tetanus and pertussis vaccines. Methods. Two hundred seven infants were randomized to receive three doses of either nonavalent protein conjugate pneumococcal vaccine (PnCV) or inactivated polio vaccine (IPV) at 2, 3 and 4 months of age with routine Expanded Program of Immunization vaccines as scheduled. Vaccinees were visited on Days 1, 2 and 7 to observe local and systemic adverse reactions. Blood was drawn before the first dose and 1 month after the third dose. Antibody concentrations in sera were measured by standardized enzyme-linked immunosorbent assay. Nasopharyngeal carriage of pneumococci was tested at 5 and 9 months of age. Results. No serious reactions were observed. Local induration and tenderness were observed more commonly at the site of administration of diphtheria, tetanus and pertussis vaccines than at the site of administration of IPV or PnCV. Between 79 and 91% achieved ≥1 μg/ml antibody against specific pneumococcal serotypes. Antibody responses to diphtheria and pertussis antigens were similar in both groups; however, antibody response to tetanus toxoid was significantly lower in infants who received PnCV (geometric mean concentration, 11.1 vs. 17.4; P < 0.001). Nasopharyngeal carriage in PnCV-vaccinated children was reduced but not significantly different from those vaccinated with IPV. Conclusion. Simultaneous administration of PnCV with Expanded Program of Immunization vaccines is safe and immunogenic. Immune response to the composite antigens is likely to confer protection.

KW - Immunogenicity

KW - Pneumococcal conjugate vaccine

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0034066122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034066122&partnerID=8YFLogxK

U2 - 10.1097/00006454-200005000-00014

DO - 10.1097/00006454-200005000-00014

M3 - Article

C2 - 10819345

AN - SCOPUS:0034066122

VL - 19

SP - 463

EP - 469

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 5

ER -